13th Mar 2012 18:30 - 13th Mar 2012 19:30


1 hour


Adam Christie - Archangel, John Waddell - Archangel


Auditorium - Business School, 29 Buccleuch Place, Edinburgh


Ruth Greig


Registration from 6pm with tea/coffee.

This is the third in a series of three joint events between Archangel Informal Investment and the Entrepreneurship Club. In this event we will hear from two of Scotlands leading business angels, John Waddell and Adam Christie. Coffee will be served from 6pm and the talks will be followed by a wine and networking reception.

John Waddell, Chief Executive - Archangel Informal Investment Ltd.

Before joining Archangels John had a number of senior roles in Scottish business. At Christian Salvesen he led a team managing group legal matters including all business investment and divestment activity and major banking transactions. He ran 63 acquisitions and disposals, playing a major role in the demerger of Aggreko from Salvesen.

At Bank of Scotland he was involved in strategic planning and various transactions including the sale of an investment management business and a major work out in the shipping division. Work on the management of investments in private companies and advisory work on M&As continued at Noble Grossart.

This experience has been put to good use at Archangels where John is responsible for leading investments of around £10million per annum in young Scottish companies. He has managed two recent exits - Mpathy Medical Devices and Lab901 and is looking at further opportunities to realise value.

He has advised and consulted with numerous government bodies including the Scottish Government; Scottish Enterprise; The Scottish Investment Bank; The Treasury; B.I.S; HMRC; and Capital for Enterprise.

Adam Christie:
Adam has a broad background in the pharmaceutical and biotechnology industries. He is a business developer and marketer with direct experience of drug and device development and the capital markets. In his last full-time role, as Chief Business Officer at PowderMed he led business development and commercial strategy which culminated in the successful sale of the company to Pfizer in late 2006 for over $300m, two and a half years after a series A venture funding round.

He is now on the Boards of two Archangels portfolio companies; Chairman at MGB Biopharma and a non-executive Director at LUX Innovate. His earlier career included roles in business development, marketing and R&D at PPL Therapeutics, GlaxoSmithKline, Abbott Laboratories and Schering AG, and as a City analyst at ABN Amro Hoare Govett. His educational background includes a BSc in Pharmacology from Southampton University and an MBA from Warwick Business School.